These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 20337745)
1. Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making? Morton AR; Murphy S; Hirsch D; Leblanc M; Barré P; Lok C; Hercz G; Hodsman A; Reslerova M; Levin A Hemodial Int; 2010 Apr; 14(2):200-10. PubMed ID: 20337745 [TBL] [Abstract][Full Text] [Related]
2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523 [TBL] [Abstract][Full Text] [Related]
3. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program. Wazny LD; Raymond CB; Lesperance EM; Bernstein KN CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010 [TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
5. RenaGel efficacy in severe secondary hyperparathyroidism. Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746 [TBL] [Abstract][Full Text] [Related]
6. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307 [TBL] [Abstract][Full Text] [Related]
7. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients. Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H; Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003 [TBL] [Abstract][Full Text] [Related]
8. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962 [TBL] [Abstract][Full Text] [Related]
9. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Wald R; Tentori F; Tighiouart H; Zager PG; Miskulin DC Am J Kidney Dis; 2007 Feb; 49(2):257-66. PubMed ID: 17261428 [TBL] [Abstract][Full Text] [Related]
10. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study. Lee CT; Tsai YC; Ng HY; Su Y; Lee WC; Lee LC; Chiou TT; Liao SC; Hsu KT J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976 [TBL] [Abstract][Full Text] [Related]
11. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T; Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160 [TBL] [Abstract][Full Text] [Related]
12. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. Salusky IB; Foley J; Nelson P; Goodman WG N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306 [TBL] [Abstract][Full Text] [Related]
13. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739 [TBL] [Abstract][Full Text] [Related]
14. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. Walsh M; Manns BJ; Klarenbach S; Tonelli M; Hemmelgarn B; Culleton B Hemodial Int; 2010 Apr; 14(2):174-81. PubMed ID: 20041960 [TBL] [Abstract][Full Text] [Related]
15. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients. Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864 [TBL] [Abstract][Full Text] [Related]
16. Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost. Gray NA; Krishnasamy R; Vardesh DL; Hollett PR; Anstey CM Nephrology (Carlton); 2011 Nov; 16(8):688-96. PubMed ID: 21649793 [TBL] [Abstract][Full Text] [Related]
17. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD. Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490 [TBL] [Abstract][Full Text] [Related]
18. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease. Panawong W; Chaiyakum A; Pongskul C J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212 [TBL] [Abstract][Full Text] [Related]
20. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]